| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441981 | European Journal of Cancer | 2015 | 18 Pages |
Abstract
Switch maintenance with pazopanib following platinum-based chemotherapy in advanced NSCLC patients had limited side-effects. This study was stopped due to lack of efficacy by stringent criteria for PFS at a futility interim analysis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mary E.R. O'Brien, Rabab Gaafar, Baktiar Hasan, Jessica Menis, Tanja Cufer, Sanjay Popat, Penella J. Woll, Veerle Surmont, Vassilis Georgoulias, Ana Montes, Fiona Blackhall, Ivo Hennig, Gerald Schmid-Bindert, Paul Baas, EORTC-LCG EORTC-LCG,